Skip to main content

Vosoritide Treatment in Children with Hypochondroplasia: Three-Year Results from a Phase 2 Extension Trial

In brief

Vosoritide kept growth 1.9 cm/year faster after three years in 13 children

In 13 children with hypochondroplasia who responded well initially, average annual growth rose from 4.27 cm/year at baseline to 6.13 cm/year after three years of daily vosoritide, while height scores improved by 0.72 standard deviations. No new safety concerns emerged, but the small, selected group means results may not predict benefit for all children.

Journal
Genetics in medicine : official journal of the American College of Medical Genetics (Q1)
Published
16 November 2026
Study design
Non-randomized / quasi-experimental trial
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Giulia Del Medico, Anqing Zhang, Roopa Kanakatti Shankar, Kimberly Pitner, Niusha Shafaei, Raheem Seaforth, et al.
PMID
43037046
DOI
10.1016/j.gim.2026.102803

Why clinicians should know about it

  • Picked for Genetics (clinical) (paper of the day, 18 November 2026): Targeted therapy trial for genetic hypochondroplasia

Abstract

PURPOSE: Vosoritide is a C-type natriuretic peptide analog approved for achondroplasia and under investigation for selected genetic causes of short stature. We previously reported the 12-months results of a phase 2 trial in children with hypochondroplasia (NCT04219007). Here, we report safety and efficacy outcomes from the three-year extension phase. METHODS: After completing a 6-month observation period followed by 12 months of daily subcutaneous vosoritide (15 μg/kg/day), participants with an increase in annualized growth velocity (AGV) >1.6 cm/year compared to baseline were eligible to continue in an open-label extension phase. RESULTS: Thirteen participants entered the extension phase and completed three years of treatment. Mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching -2.64±0.79 SD on the CDC growth charts. A similar increase was observed on the hypochondroplasia-specific charts (0.83 SD). Mean AGV increased from 4.27±0.70 cm/year at baseline to 7.24±0.80 cm/year at Year 1 and remained above baseline at Year 3 (6.13±1.27 cm/year). No new safety concerns were identified. CONCLUSION: Vosoritide was associated with sustained improvements in growth in a selected cohort of initial good responders with hypochondroplasia. The treatment was well tolerated. Limitations of the extension study include selection bias and a small sample size.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.